Immunogenicity , antibody persistence , and safety of the EU-licensed meningococcal ACWY-tetanus toxoid conjugate vaccine ( MenACWY-TT ) were evaluated in healthy participants aged 11-55 years from the Philippines and Saudi Arabia .
